|
- Paul Monahan, MD
- An Open-Label Study To Evaluate Prophylaxis Treatment, And To Characterize The Efficacy, Safety, and Pharmacokinetics Of B-Domain Deleted Recombinant Factor VIII Albumin Free (ReFacto(R) AF) In Children With Hemophilia A
- Joseph Muenzer, MD, PhD
- A Phase 2, Multicenter, Open-Label Study to evaluate the Safety and Efficacy of Phenoptin in Subjects with Hyperpheylalaninemia Due to Primary BH4 Deficiency
- Marianne Muhlebach, MD
- A Randomized, Double Blind, Placebo Controlled, Parallel Group Study Investigating the Safety and Efficacy over a 12 Week Treatment Period of MAP0010 in Asthmatic Infants and Children 12 Months to 8 Years of Age
|
